Stimulation of topoisomerase II-mediated DNA cleavage by an indazole analogue of lucanthone

Biochemical Pharmacology

Volumn 58, Issue 8, 1999, Pages 1307-1312

  Dassonneville, Laurent ^a   Bailly, Christian ^a  

^a IRCL   (France)

Author keywords

Antitumour agents; DNA cleavage; Lucanthone; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); INDAZOLE DERIVATIVE; LUCANTHONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CHROMATOPHORE; CONTROLLED STUDY; CYTOTOXICITY; DNA CLEAVAGE; DRUG BINDING; DRUG STRUCTURE; NONHUMAN; PRIORITY JOURNAL; RESTRICTION FRAGMENT; SEQUENCE ANALYSIS;

DNA; DNA TOPOISOMERASES, TYPE II; HUMANS; INDAZOLES; LUCANTHONE; MOLECULAR STRUCTURE;

EID: 0032839674     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00221-X     Document Type: Article

References (26)

1. Wang J.C. DNA topoisomerases. Annu Rev Biochem. 65:1996;635-691.
2. Burden D.A., Osheroff N. Mechanism of action of eukaryotic topoisomerase II and drugs targeted to the enzyme. Biochim Biophys Acta. 1400:1998;139-154.
3. Wang H.-K., Morris-Natschke S.L., Lee K.-H. Recent advances in the discovery and development of topoisomerase inhibitors as antitumor agents. Med Res Rev. 17:1997;367-425.
4. Kreuzer K.N. DNA topoisomerases as potential targets of antiviral action. Pharmacol Ther. 43:1989;377-395.
5. Hirschberg E, Thiaxanthenones: Miracil D and hycanthone. In: Antibiotics. III. Mechanism of Action of Antimicrobial and Antitumour Agents (Eds. Corcoran JW and Hahn FE), pp. 274-303, Springer-Verlag, Heidelberg, 1975.
6. Turner S., Bases R., Pearlman A., Nobler M., Kabakow B. The adjuvant effect of lucanthone (Miracil D) in clinical radiation therapy. Radiology. 114:1975;729-731.
7. Nobler M.P., Scher A.J. Lucanthone as a radiosensitizing agent in the treatment of carcinoma of the cervix. Int J Radiat Oncol Biol Phys. 4:1978;1039-1044.
8. Del Rowe J.D., Bello J., Mitnick R., Sood B., Filippi C., Moran J., Freeman K., Mendez F., Bases R. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radiat Oncol Biol Phys. 42:1999;89-93.
9. Bases R.E., Mendez F. Topoisomerase inhibition by lucanthone, an adjuvant in radiation therapy. Int J Radiat Oncol Biol Phys. 37:1997;1133-1137.
10. Waring M.J. Interaction of indazole analogs of lucanthone and hycanthone with closed circular duplex deoxyribonucleic acid. J Pharmacol Exp Ther. 186:1973;385-389.
11. Bailly C., Waring M.J. Preferential intercalation at AT sequences in DNA by lucanthone, hycanthone, and indazole analogs. A footprinting study. Biochemistry. 32:1993;5985-5993.
12. Werbel L.M., Elslager E.F., Ortwine D.F., Shillis J.L., Showalter H.D.H., Worth D.F., Plowman J. 2′-(Aminoalkyl)-5-amino-2H-[1]benzothiopyrano[4,3,2-cd)indazoles, a new class of anticancer agents. Proc Am Assoc Cancer Res. 26:1985;254.
13. Kawakami Y., Hopfinger A.J. Molecular dynamic simulations of the intercalation of benzothiopyranoindazole anti-cancer analogs with DNA models. Anticancer Drug Des. 7:1992;181-201.
14. Hopfinger A.J., Kawakami Y. QSAR analysis of a set of benzothiopyranoindazole anti-cancer analogs based upon their DNA intercalation properties as determined by molecular dynamics simulation. Anticancer Drug Des. 7:1992;203-217.
15. Perni R.B., Wentland M.P., Huang J.I., Powles R.G., Aldous S., Klingbeil K.M., Peverly A.D., Robinson R.G., Corbett T.H., Jones J.L., Mattes K.C., Rake J.B., Coughlin S.A. Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylthiopyranoindazole derivatives. J Med Chem. 41:1998;3645-3654.
16. Fry D.W., Besserer J.A. Biochemical pharmacology and DNA-drug interaction by CI-958, a new antitumor intercalator derived from a series of substituted 2H-[1]benzothiopyrano[4,3,2-cd)indazoles. Mol Pharmacol. 33:1988;84-92.
17. Showalter H.D.H., Angelo M.M., Berman E.M., Kanter G.D., Ortwine D.F., Ross-Kesten S.G., Sercel A.D., Turner W.R., Werbel L.M., Worth D.F., Elslager E.F., Leopold W.R., Shillis J.L. Benzothiopyranoindazoles, a new class of chromophore-modified anthracenedione anticancer agents. Synthesis and activity against murine leukemias. J Med Chem. 31:1988;1527-1539.
18. Hartley J.A., Reszska K., Zuo E.T., Wilson W.D., Morgan A.R., Lown J.W. Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids Structural requirements for DNA binding, intercalation, and photosensitization . Mol Pharmacol. 33:1988;265-271.
19. Sebolt J.S., Scavone S.V., Pinter C.D., Hamelehle K.L., Von Hoff D.D., Jackson R.C. Pyrazoloacridines, a new class of anticancer agents with selectivity against solid tumors in vitro. Cancer Res. 47:1987;4299-4304.
20. Kerckaert J.P., Deweindt C., Tilly H., Quief S., Lecocq G., Bastard C. LAZ3, a novel zinc-finger encoding gene, is disrupted by recurring chromosome 3q27 translocations in human lymphomas. Nature Genet. 5:1993;66-70.
21. Capranico G., Kohn K.W., Pommier Y. Local sequence requirements for DNA cleavage by mammalian topoisomerase II in the presence of doxorubicin. Nucleic Acids Res. 18:1990;6611-6619.
22. Capranico G., De Isabella P., Tinelli S., Bigioni M., Zunino F. Similar sequence specificity of mitoxantrone and VM-26 stimulation of in vitro DNA cleavage by mammalian DNA topoisomerase II. Biochemistry. 32:1994;3038-3046.
23. Leteurtre F., Kohlagen G., Paull K.D., Pommier Y. Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen. J Natl Cancer Inst. 86:1994;1239-1244.
24. Bailly C., Routier S., Bernier J.L., Waring M.J. DNA recognition by two mitoxantrone analogues Influence of the hydroxyl groups . FEBS Lett. 379:1996;269-272.
25. Chaires J.B., Herrera J.E., Waring M.J. Preferential binding of daunomycin to 5′(A/T)CG and 5′(A/T)GC sequences revealed by footprinting titration experiments. Biochemistry. 29:1990;6145-6153.
26. Capranico G., Binaschi M. DNA sequence selectivity of topoisomerases and topoisomerase poisons. Biochim Biophys Acta. 1400:1988;185-194.